These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
183 related articles for article (PubMed ID: 37963936)
1. Synthesis, molecular docking, and in vivo antidiabetic evaluation of new benzylidene-2,4-thiazolidinediones as partial PPAR-γ agonists. Najmi A; Alam MS; Thangavel N; Taha MME; Meraya AM; Albratty M; Alhazmi HA; Ahsan W; Haque A; Azam F Sci Rep; 2023 Nov; 13(1):19869. PubMed ID: 37963936 [TBL] [Abstract][Full Text] [Related]
2. Synthesis, docking, in vitro and in vivo antidiabetic activity of pyrazole-based 2,4-thiazolidinedione derivatives as PPAR-γ modulators. Naim MJ; Alam O; Alam MJ; Shaquiquzzaman M; Alam MM; Naidu VGM Arch Pharm (Weinheim); 2018 Apr; 351(3-4):e1700223. PubMed ID: 29400412 [TBL] [Abstract][Full Text] [Related]
3. Design, Synthesis, and Biological Evaluation of Thiazolidine-2,4-dione Conjugates as PPAR-γ Agonists. Nazreen S; Alam MS; Hamid H; Shahar Yar M; Dhulap A; Alam P; Pasha MA; Bano S; Alam MM; Haider S; Kharbanda C; Ali Y; Pillai K Arch Pharm (Weinheim); 2015 Jun; 348(6):421-32. PubMed ID: 25900064 [TBL] [Abstract][Full Text] [Related]
4. Thiazolidine-2,4-diones derivatives as PPAR-γ agonists: synthesis, molecular docking, in vitro and in vivo antidiabetic activity with hepatotoxicity risk evaluation and effect on PPAR-γ gene expression. Nazreen S; Alam MS; Hamid H; Yar MS; Dhulap A; Alam P; Pasha MA; Bano S; Alam MM; Haider S; Kharbanda C; Ali Y; Pillai KK Bioorg Med Chem Lett; 2014 Jul; 24(14):3034-42. PubMed ID: 24890090 [TBL] [Abstract][Full Text] [Related]
5. Identification of Selective PPAR-γ Modulators by Combining Pharmacophore Modeling, Molecular Docking, and Adipogenesis Assay. Li Y; Ks N; Byran G; Krishnamurthy PT Appl Biochem Biotechnol; 2023 Feb; 195(2):1014-1041. PubMed ID: 36264481 [TBL] [Abstract][Full Text] [Related]
6. Rational design and synthesis of some PPAR-γ agonists: Substituted benzylideneamino-benzylidene-thiazolidine-2,4-diones. Chhajed SS; Chaskar S; Kshirsagar SK; Haldar GM; Kar Mahapatra D Comput Biol Chem; 2017 Apr; 67():260-265. PubMed ID: 28193552 [TBL] [Abstract][Full Text] [Related]
7. Oxadiazolyl thiazolidinedione as a non-adipogenic PPAR-γ partial agonist and its effect on glucose homeostasis in type 2 diabetes. Thangavel N; Bratty MA; Javed SA; Ahsan W; Hazmi HA J Biol Regul Homeost Agents; 2019; 33(3):707-719. PubMed ID: 31204468 [TBL] [Abstract][Full Text] [Related]
8. Integrated fragment-based drug design and virtual screening techniques for exploring the antidiabetic potential of thiazolidine-2,4-diones: Design, synthesis and in vivo studies. Gupta S; Baweja GS; Singh S; Irani M; Singh R; Asati V Eur J Med Chem; 2023 Dec; 261():115826. PubMed ID: 37793328 [TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, in silico molecular docking and biological evaluation of novel oxadiazole based thiazolidine-2,4-diones bis-heterocycles as PPAR-γ agonists. Nazreen S; Alam MS; Hamid H; Yar MS; Shafi S; Dhulap A; Alam P; Pasha MA; Bano S; Alam MM; Haider S; Ali Y; Kharbanda C; Pillai KK Eur J Med Chem; 2014 Nov; 87():175-85. PubMed ID: 25255433 [TBL] [Abstract][Full Text] [Related]
10. Synthesis, characterization, biological evaluation and docking of coumarin coupled thiazolidinedione derivatives and its bioisosteres as PPARγ agonists. Shukla S; Kumar P; Das N; Moorthy NS; Shrivastava SK; Trivedi P; Srivastava RS Med Chem; 2012 Sep; 8(5):834-45. PubMed ID: 22741802 [TBL] [Abstract][Full Text] [Related]
11. T2384, a novel antidiabetic agent with unique peroxisome proliferator-activated receptor gamma binding properties. Li Y; Wang Z; Furukawa N; Escaron P; Weiszmann J; Lee G; Lindstrom M; Liu J; Liu X; Xu H; Plotnikova O; Prasad V; Walker N; Learned RM; Chen JL J Biol Chem; 2008 Apr; 283(14):9168-76. PubMed ID: 18263587 [TBL] [Abstract][Full Text] [Related]
12. INT131: a selective modulator of PPAR gamma. Motani A; Wang Z; Weiszmann J; McGee LR; Lee G; Liu Q; Staunton J; Fang Z; Fuentes H; Lindstrom M; Liu J; Biermann DH; Jaen J; Walker NP; Learned RM; Chen JL; Li Y J Mol Biol; 2009 Mar; 386(5):1301-11. PubMed ID: 19452630 [TBL] [Abstract][Full Text] [Related]
13. Novel Benzylidene Thiazolidinedione Derivatives as Partial PPARγ Agonists and their Antidiabetic Effects on Type 2 Diabetes. Yasmin S; Capone F; Laghezza A; Piaz FD; Loiodice F; Vijayan V; Devadasan V; Mondal SK; Atlı Ö; Baysal M; Pattnaik AK; Jayaprakash V; Lavecchia A Sci Rep; 2017 Oct; 7(1):14453. PubMed ID: 29089569 [TBL] [Abstract][Full Text] [Related]
14. MBX-102/JNJ39659100, a novel peroxisome proliferator-activated receptor-ligand with weak transactivation activity retains antidiabetic properties in the absence of weight gain and edema. Gregoire FM; Zhang F; Clarke HJ; Gustafson TA; Sears DD; Favelyukis S; Lenhard J; Rentzeperis D; Clemens LE; Mu Y; Lavan BE Mol Endocrinol; 2009 Jul; 23(7):975-88. PubMed ID: 19389808 [TBL] [Abstract][Full Text] [Related]
15. Discovery of thiazolidine-2,4-dione/biphenylcarbonitrile hybrid as dual PPAR α/γ modulator with antidiabetic effect: in vitro, in silico and in vivo approaches. Hidalgo-Figueroa S; Ramírez-Espinosa JJ; Estrada-Soto S; Almanza-Pérez JC; Román-Ramos R; Alarcón-Aguilar FJ; Hernández-Rosado JV; Moreno-Díaz H; Díaz-Coutiño D; Navarrete-Vázquez G Chem Biol Drug Des; 2013 Apr; 81(4):474-83. PubMed ID: 23289972 [TBL] [Abstract][Full Text] [Related]
16. A novel non-agonist peroxisome proliferator-activated receptor γ (PPARγ) ligand UHC1 blocks PPARγ phosphorylation by cyclin-dependent kinase 5 (CDK5) and improves insulin sensitivity. Choi SS; Kim ES; Koh M; Lee SJ; Lim D; Yang YR; Jang HJ; Seo KA; Min SH; Lee IH; Park SB; Suh PG; Choi JH J Biol Chem; 2014 Sep; 289(38):26618-26629. PubMed ID: 25100724 [TBL] [Abstract][Full Text] [Related]
17. Identification of novel multitargeted PPARα/γ/δ pan agonists by core hopping of rosiglitazone. Wang XJ; Zhang J; Wang SQ; Xu WR; Cheng XC; Wang RL Drug Des Devel Ther; 2014; 8():2255-62. PubMed ID: 25422585 [TBL] [Abstract][Full Text] [Related]
18. Uncovering PPAR-γ agonists: An integrated computational approach driven by machine learning. Haider S; Shafiq M; Siddiqui AR; Sardar M; Mushtaq M; Shafeeq S; Nur-E-Alam M; Ahmad A; Ul-Haq Z J Mol Graph Model; 2024 Jun; 129():108742. PubMed ID: 38422823 [TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, and biological evaluation of a series of alkoxy-3-indolylacetic acids as peroxisome proliferator-activated receptor γ/δ agonists. Gim HJ; Li H; Jeong JH; Lee SJ; Sung MK; Song MY; Park BH; Oh SJ; Ryu JH; Jeon R Bioorg Med Chem; 2015 Jul; 23(13):3322-36. PubMed ID: 25982078 [TBL] [Abstract][Full Text] [Related]
20. GQ-16, a novel peroxisome proliferator-activated receptor γ (PPARγ) ligand, promotes insulin sensitization without weight gain. Amato AA; Rajagopalan S; Lin JZ; Carvalho BM; Figueira AC; Lu J; Ayers SD; Mottin M; Silveira RL; Souza PC; Mourão RH; Saad MJ; Togashi M; Simeoni LA; Abdalla DS; Skaf MS; Polikparpov I; Lima MC; Galdino SL; Brennan RG; Baxter JD; Pitta IR; Webb P; Phillips KJ; Neves FA J Biol Chem; 2012 Aug; 287(33):28169-79. PubMed ID: 22584573 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]